Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Potential Role of Receptor for Advanced Glycation End-Products, Serum, Krebs Von Den Lungen-6, and Surfactant Protein D as Prognostic Factors in Children With Severe Acute Respiratory Syndrome (SARS-CoV-2)

NCT05619640 is registered in ClinicalTrials.gov with Haseki Training and Research Hospital as lead sponsor.

NCT NCT05619640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05619640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Potential Role of Receptor for Advanced Glycation End-Products, Serum, Krebs Von Den Lungen-6, and Surfactant Protein D as Prognostic Factors in Children With Severe Acute Respiratory Syndrome (SARS-CoV-2)
Lead sponsor
Haseki Training and Research Hospital
Phase
Observational
Overall status
Completed
Start date
July 1, 2021
Completion date
September 30, 2022
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar; injury, children, pneumonia, viral, sars cov 2 infection